Quest Diagnostics
DGX
$145.63
Share price
-0.91%
Change (1 day)
7.99%
Change (1 year)
Categories
Quest Diagnostics is an American clinical laboratory company offering access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders and employment and court ordered drug testing.
P/S ratio for Quest Diagnostics (DGX)
P/S ratio as of January 2023 (TTM): 1.61
According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.61117. At the end of 2022 the company had a P/S ratio of 1.39.
P/S ratio history for Quest Diagnostics from 2001 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 1.39 | -29.36% |
| 2021 | 1.97 | 15.6% |
| 2020 | 1.70 | -7.43% |
| 2019 | 1.84 | 23.16% |
| 2018 | 1.49 | -14.28% |
| 2017 | 1.74 | 2.71% |
| 2016 | 1.70 | 24.88% |
| 2015 | 1.36 | 4.53% |
| 2014 | 1.30 | 20.38% |
| 2013 | 1.08 | -13.67% |
| 2012 | 1.25 | 2.47% |
| 2011 | 1.22 | -2.46% |
| 2010 | 1.25 | -15.77% |
| 2009 | 1.48 | 5.99% |
| 2008 | 1.40 | -8.56% |
| 2007 | 1.53 | -6.53% |
| 2006 | 1.64 | -11.71% |
| 2005 | 1.86 | -1.58% |
| 2004 | 1.89 | 18.89% |
| 2003 | 1.59 | 16.92% |
| 2002 | 1.36 | -28.51% |
| 2001 | 1.90 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 LabCorp LH | 1.48 | -8.35% | 🇺🇸 USA |
 Translate Bio
TBIO | N/A | -100.00% | 🇺🇸 USA |
 Psychemedics PMD | 1.21 | -25.14% | 🇺🇸 USA |
 NeoGenomics
NEO | 2.93 | 81.64% | 🇺🇸 USA |
 Qiagen QGEN | 5.04 | 213.01% | 🇳🇱 Netherlands |
 Enzo Biochem ENZ | 0.6951 | -56.86% | 🇺🇸 USA |